Sotsiaalministeerium · 20. november 2020
Sisu (failidest)
JADECARE Consortium Agreement - Final version , 2020-10-26
CONSORTIUM AGREEMENT
JOINT ACTION ON IMPLEMENTATION OF DIGITALLY
ENABLED INTEGRATED PERSON-CENTERED CARE
- JADECARE
Bilbao, Basque Country-Spain
October 26th 2020
1 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
Table of Content
CONSORTIUM AGREEMENT ................................................................................................................ 3
1 Section: Definitions ....................................................................................................................... 4
2 Section: Purpose ........................................................................................................................... 5
3 Section: Entry into force, duration and termination .................................................................. 5
4 Section: Responsibilities of Beneficiaries .................................................................................. 6
5 Section: Liability towards each other .......................................................................................... 8
6 Section: Governance structure .................................................................................................... 9
7 Section: Financial provisions..................................................................................................... 18
8 Section: Results........................................................................................................................... 19
9 Section: Access Rights ............................................................................................................... 22
10 Section: Non-disclosure of information .................................................................................... 24
11 Section: Miscellaneous ............................................................................................................... 26
12 Section Signatures ...................................................................................................................... 28
Attachment 1: Accession document ................................................................................................. 45
Attachment 2: List of Affiliated Entities ............................................................................................ 46
2 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
CONSORTIUM AGREEMENT
This Consortium Agreement is a private reciprocal agreement between the beneficiaries of
the Joint Action JADECARE, to set out the rights and obligations amongst themselves. (It
does not involve the European Commission nor CHAFEA). It complements the Grant
Agreement and does not contain any provision contrary to it. It must be signed by all
beneficiaries.
THIS CONSORTIUM AGREEMENT is based upon the Grant Agreement with the
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) for the Joint Action
entitled “Joint Action on implementation of Digitally Enabled integrated person-centered
CARE – JADECARE” Grant Agreement number 951442, and is effective as of 01 October
2020, hereinafter referred to as “the starting date of the Joint Action” and “Effective Date”.
BETWEEN:
1. ASOCIACIÓN INSTITUTO DE INVESTIGACIÓN EN SERVICIOS DE SALUD- KRONIKGUNE
(KG), the coordinator,
2. MINISTRY OF CIVIL AFFAIRS (MCA), Bosnia and Herzegovina,
3. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH), Croatia,
4. MINISTERSTVO ZDRAVOTNICTVI CESKE REPUBLIKY (MZCR), Czech Republic,
5. REGION NORDJYLLAND (NORTH DENMARK REGION) (RND), Denmark,
6. SOTSIAALMINISTEERIUM (MSAE), Estonia,
7. EUROMETROPOLE DE STRASBOURG (EUSTRAS), France,
8. BEHOERDE FUER ARBEIT, GESUNDHEIT, SOZIALES, FAMILIE UND INTEGRATION HAMBURG
(BAGSFI), Germany,
9. 4I DIOIKISI YGEIONOMIKIS PERIFEREIAS MAKEDONIAS KAI THRAKIS (4THYPE), Greece,
10. ALLAMI EGESZSEGUGYI ELLATO KOZPONT (AEEK), Hungary,
11. AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI (AGENAS), Italy,
12. NACIONALAIS VESELIBAS DIENESTS (NVD), Latvia,
13. LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (LR SAM), Lithuania,
14. ADMINISTRACAO CENTRAL DO SISTEMA DESAUDE IP (ACSS), Portugal,
15. MINISTARSTVO ZDRAVLJA (MoHRS), Serbia,
16. NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ), Slovenia,
17. REGIONAL HEALTH AND SOCIAL CARE BOARD (HSCB), United Kingdom,
hereinafter, jointly or individually, referred to as “Beneficiaries” or “Beneficiary”
relating to the Joint Action entitled “JOINT ACTION ON IMPLEMENTATION OF DIGITALLY
ENABLED INTEGRATED PERSON-CENTERED CARE”
in short JADECARE
hereinafter referred to as “Joint Action (JA)”
3 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
WHEREAS:
The Beneficiaries, having considerable experience in the field concerned, have submitted a
proposal for the Joint Action to CHAFEA as part of the 3rd. EU Health Programme (2014-
2020).
The Competent Authorities wish to specify or supplement binding commitments among
themselves in addition to the provisions of the specific Grant Agreement to be signed by the
Competent Authorities and the Funding Authority (hereinafter “Grant Agreement”).
The Beneficiaries are aware that this Consortium Agreement is based upon the DESCA model
consortium agreement.
NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:
1 Section: Definitions
1.1 Definitions
Words beginning with a capital letter shall have the meaning defined either herein or in the
Rules for Participation or in the Grant Agreement including its Annexes.
1.2 Additional Definitions
“Beneficiary or Beneficiaries” means a beneficiary or the beneficiaries to this Consortium
Agreement also identified as the beneficiaries to the Grant Agreement.
“Coordination Team”. The Coordination Team (CT) forms an integral part of the
Coordinator and both terms will be used interchangeably.
“Competent Authority” (CA) means the central authority of a Member State competent for
health/specific (public) health topic or any other authority to which that competence has
been conferred; it shall also include, where appropriate, the corresponding authority of a
third country. A Competent Authority can also be one at regional level, depending on the
governance structure of the Member State/third country.
“Affiliated Entity” (AE) - entities affiliated to the nominated Competent Authorities:
these are organizations that have a distinct legal personality but are linked to the
nominated Competent Authority.
“Consortium Body“ means any management body described in the Governance Structure
section of this Consortium Agreement.
“Consortium Plan” means the description of the action and the related agreed budget as
first defined in the Grant Agreement and which may be updated by the General Assembly.
"Funding Authority," means the body awarding the grant for the Joint Action.
4 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
“Force Majeure”
“Force Majeure” means any one or more events beyond the reasonable control of the
relevant Party which occur after the date of signing of this Consortium Agreement, were not
reasonably foreseeable at the time of signing of this Consortium Agreement, and the effects
of which are not capable of being overcome without unreasonable expense and/or
unreasonable loss of time to the Party concerned. Force Majeure events shall include
(without limitation) war, civil unrest, acts of government, natural disasters, exceptional
weather conditions, breakdown or general unavailability of transport facilities, accidents, fire,
explosions, and general shortages of energy.
“Defaulting Beneficiary” means a Beneficiary which the General Assembly has identified to
be in breach of this Consortium Agreement and/or the Grant Agreement as specified in
Section 4.2 of this Consortium Agreement.
“Needed” means:
For the implementation of the Joint Action:
Access Rights are Needed if, without the grant of such Access Rights, carrying out the tasks
assigned to the recipient Beneficiary would be technically or legally impossible, significantly
delayed, or require significant additional financial or human resources.
For Exploitation of own Results:
Access Rights are Needed if, without the grant of such Access Rights, the Exploitation of
own Results would be technically or legally impossible.
2 Section: Purpose
The purpose of this Consortium Agreement is to specify with respect to the Joint Action the
relationship among the Beneficiaries, in particular concerning the organisation of the work
between the Beneficiaries, the management of the Joint Action and the rights and
obligations of the Beneficiaries concerning inter alia liability, Access Rights and dispute
resolution.
3 Section: Entry into force, duration and termination
3.1 Entry into force
An entity becomes a Beneficiary to this Consortium Agreement upon signature of this
Consortium Agreement by a duly authorized representative.
This Consortium Agreement shall have effect from the Effective Date identified in the Grant
Agreement.
A new entity becomes a Beneficiary to the Consortium Agreement upon signature of the
accession document (Attachment 1) by the new Beneficiary and the Coordinator. Such
accession shall have effect from the date identified in the accession document.
3.2 Duration and termination
This Consortium Agreement shall continue in full force and effect until complete fulfilment of
all obligations undertaken by the Beneficiaries under the Grant Agreement and under this
Consortium Agreement.
5 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
However, this Consortium Agreement or the participation of one or more Beneficiaries may
be terminated in accordance with the terms of this Consortium Agreement.
If
- the Grant Agreement is not signed by the Funding Authority or a Beneficiary, or
- the Grant Agreement is terminated, or
- a Beneficiary's participation in the Grant Agreement is terminated,
this Consortium Agreement shall automatically terminate in respect of the affected
Beneficiary/ies, subject to the provisions surviving the expiration or termination under Section
3 of this Consortium Agreement.
3.3 Survival of rights and obligations
The provisions relating to Access Rights, Dissemination and Confidentiality, for the time
period mentioned therein, as well as for liability, applicable law and settlement of disputes
shall survive the expiration or termination of this Consortium Agreement.
Termination shall not affect any rights or obligations of a Beneficiary leaving the Consortium
incurred prior to the date of termination, unless otherwise agreed between the General
Assembly and the leaving Beneficiary. This includes the obligation to provide all input,
deliverables and documents for the period of its participation.
4 Section: Responsibilities of Beneficiaries
4.1 General principles
Each Beneficiary undertakes to take part in the efficient implementation of the Joint Action,
and to cooperate, perform and fulfil, promptly and on time, all of its obligations under the
Grant Agreement and this Consortium Agreement as may be reasonably required from it and
in a manner of good faith as prescribed by Belgian law.
Each Beneficiary undertakes to notify promptly, in accordance with the governance structure
of the Joint Action, any significant information, fact, problem or delay likely to affect the Joint
Action.
Each Beneficiary shall promptly provide all information reasonably required by a Consortium
Body or by the Coordinator to carry out its tasks.
Each Beneficiary shall take reasonable measures to ensure the accuracy of any information
or materials it supplies to the other Beneficiaries.
4.2 Breach
In the event that a responsible Consortium Body identifies a breach by a Beneficiary of its
obligations under this Consortium Agreement or the Grant Agreement (e.g. improper
implementation of the Joint Action), the Coordinator or, if the Coordinator is in breach of its
obligations, the Beneficiary appointed by the General Assembly, will give formal notice to
such Beneficiary requiring that such breach will be remedied within 30 calendar days from
the date of receipt of the written notice by the Beneficiary.
If such breach is substantial, as mention on the Grant Agreement Article 7, and is not
remedied within that period or is not capable of remedy, the General Assembly may decide
to declare the Beneficiary to be a Defaulting Beneficiary and to decide on the consequences
thereof that may include termination of its participation.
6 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
4.3 Involvement of third Beneficiaries
A Beneficiary that enters into a subcontract or otherwise involves third Beneficiaries
(including but not limited to Affiliated Entities) in the Joint Action remains responsible for
carrying out its relevant part of the Joint Action and for such Affiliated Entity’s compliance
with the provisions of this Consortium Agreement and of the Grant Agreement. It has to
ensure that the involvement of third Beneficiaries does not affect the rights and obligations of
the other Beneficiaries under this Consortium Agreement and the Grant Agreement.
4.4 Affiliated entities
With regards to affiliated entities, the following two options exist:
4.4.1 Affiliated entities to a beneficiary – legal or capital link
According to article 122 of the Financial Regulation an entity affiliated to a "single"
beneficiary (for Joint Actions - the competent authority) is an entity that fulfils the following
conditions:
It has a structural link with the "single" beneficiary, in particular a legal or capital link. In
general, the notion of legal and capital link encompasses mainly two notions - control and
membership. Control means that entities are directly or indirectly controlled by the
beneficiary, under the same control as the beneficiary - or controlling the beneficiary.
Membership, means that the beneficiary is defined as for example a network, federation,
association in which the affiliated entities also participate.
4.4.2 Affiliated entities forming one "Sole beneficiary" as a single entity
Article 122.1 of the Financial Regulation introduced the concept of "sole beneficiary": "Where
several entities satisfy the criteria for being awarded a grant and together form one entity,
that entity may be treated as the "sole beneficiary", including where the entity is specifically
established for the purpose of implementing the action to be financed by the grant".
The competent authority, acting as leader of or affiliated to the "sole beneficiary", must have
been nominated by the participating country. The "sole beneficiary" may be legally
established specifically for the purpose of the action. The "sole beneficiary" does not need to
have a distinct legal personality. The affiliated entities forming the "sole beneficiary" should
establish as appropriate internal arrangements setting out the functioning of the "sole
beneficiary" and the role of each one. This internal arrangement may take the form of
an internal co-operation agreement (national consortium agreement).
In both above cases, only the leader of the sole beneficiary will sign the Joint Action Grant
Agreement.
4.4.3 Legal commitment and responsibilities of the beneficiary and affiliated entities for both
options
a. The competent authority or beneficiary and its affiliated entities have to be identified in the
Grant Agreement.
b. The beneficiary is fully responsible for the implementation of the tasks assigned to its
affiliated entities, from the operational and financial point of view. Therefore: They must
inform of any change to the situation of their affiliates.
7 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
c. They are financially responsible for any amount that would have been paid as
reimbursement of costs unduly declared by its affiliated entities.
d. The beneficiary has obligations in connection to its affiliated entities, among
others: Ensuring that the eligibility criteria applying to its own costs apply also to the costs
incurred by its affiliated entities; Ensuring compliance of its affiliated entities with the rules
applying to them on nonliability of the Commission, absence of conflict of interest,
confidentiality, visibility of the Union and evaluation.
e. A beneficiary cannot subcontract tasks to its affiliated entities or to the entities affiliated to
another beneficiary in the same grant. This is considered like subcontracting activities
between different beneficiaries of a grant and is forbidden by the Financial Regulation.
5 Section: Liability towards each other
5.1 No warranties
In respect of any information or materials (incl. Results) supplied by one Beneficiary to
another under the Joint Action, no warranty or representation of any kind is made, given or
implied as to the sufficiency or fitness for purpose nor as to the absence of any infringement
of any proprietary rights of third Beneficiaries.
Therefore,
the recipient Beneficiary shall in all cases be entirely and solely liable for the use to which
it puts such information and materials, and
no Beneficiary granting Access Rights shall be liable in case of infringement of
proprietary rights of an Affiliated Entity resulting from any other Beneficiary (or its
Affiliated Entities) exercising its Access Rights.
5.2 Limitations of contractual liability
No Beneficiary shall be responsible to any other Beneficiary for any indirect or consequential
loss or similar damage such as, but not limited to, loss of profit, loss of revenue or loss of
contracts, provided such damage was not caused by a wilful act or by a breach of
confidentiality.
For any remaining contractual liability, a Beneficiary’s aggregate liability towards the other
Beneficiaries collectively shall be limited to the Beneficiary’s share of the total costs of the
Joint Action as identified in Annex 2 of the Grant Agreement provided such damage was not
caused by a wilful act or gross negligence.
The terms of this Consortium Agreement shall not be construed to amend or limit any
Beneficiary’s statutory liability.
5.3 Damage caused to third Beneficiaries
Each Beneficiary shall be solely liable for any loss, damage or injury to third Beneficiaries
resulting from the performance of the said Beneficiary’s obligations by it or on its behalf
under this Consortium Agreement or from its use of Results.
8 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
5.4 Force Majeure
No Beneficiary shall be considered to be in breach of this Consortium Agreement if it is
prevented from fulfilling its obligations under the Consortium Agreement by Force Majeure.
Each Beneficiary will notify the competent Consortium Bodies of any Force Majeure without
undue delay. If the consequences of Force Majeure for the Joint Action are not overcome
within 6 weeks after such notification, the transfer of tasks - if any - shall be decided by the
competent Consortium Bodies.
6 Section: Governance structure
6.1 General structure
The organisational structure of the Consortium shall comprise the following Consortium
Bodies:
“General Assembly (GA)” as the ultimate decision-making body of the Consortium.
“Steering Committee (SC)” as the supervisory body for the execution of the Joint Action
which shall report to and be accountable to the General Assembly.
The “Coordinator” is the legal entity acting as the intermediary between the Beneficiaries and
the Funding Authority. The Coordinator shall, in addition to its responsibilities as a
Beneficiary, perform the tasks assigned to it as described in the Grant Agreement and this
Consortium Agreement.
The “Coordination Team” is responsible for the achievement of the JA goals and the
contractual obligations towards the European Commission, and provides global scientific and
technical leadership, quality assurance policy and overall coordination of the joint action. The
Coordination Team is formed by the JA Coordinator supported by the Scientific Coordinator,
the Project Manager and the Financial Manager.
Coordination and implementation roles and activities in the Joint Action are performed by
CAs (as Leading Beneficiaries (LB)), and AEs. AEs can act as Leading Executive
Organisations (LEO) and Co-Leading Executive Organisations. CAs and AEs are responsible
for Work Packages and/or Tasks and contribute to the Deliverables and Milestones as
described in the JADECARE Joint Action.
The “Work Package lead (WPL)” is formed by the Lead Beneficiary (LB), the Leading
Executive Organization (LEO) and the co-Leading Executive Organisation. It is responsible
for the day-to-day management and coordination of the activities included in their respective
work packages as defined in the Grant Agreement, and will be able to raise proposals to the
SC regarding effort and budget redistribution, and re-assignment of roles and responsibilities
within their respective WPs.
“Next Adopters Working Groups (NAWG)” are in charge for the implementation of the Local
Good Practices, led by the representative of the corresponding Competent Authority or
Affiliated Entity.
“Policy Board (PB)” is responsible for giving input to sustainability plans from the focus of
policy, and the definition of core messages to support evidence-based policy making with
respect to sustainability of JADECARE results.
9 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
6.2 General operational procedures for all Consortium Bodies
6.2.1 Representation in meetings
Any Beneficiary which is a member of a Consortium Body (hereinafter referred to as
"Member"):
- should be present or represented at plenary meetings, GA meetings and Stakeholder
Forum.
- may appoint a substitute or a proxy to attend and vote at any meeting;
and shall participate in a cooperative manner in the meetings.
Work Package Leads should:
- be present or represented at plenary meetings and SC meetings.
- be present or represented at Work Package meetings in which they participate.
- may appoint a substitute or a proxy to attend a meeting;
and shall participate in a cooperative manner in the meetings.
CAs and AEs should:
- be present or represented at Work Package meetings in which they participate.
- may appoint a substitute or a proxy to attend a meeting;
and shall participate in a cooperative manner in the meetings.
6.2.2 Preparation and organisation of meetings
The Consortium Bodies will prepare and organize meetings according to the general rules
below. The General Assembly and the Steering Committee will comply with the specified
deadlines and rules.
6.2.2.1 Convening meetings
The chairperson of a Consortium Body shall convene meetings of that Consortium Body.
Ordinary Extraordinary meeting
meeting
General At least once At any time upon written request of the Coordinator,
Assembly a year Steering Committee or 1/3 of the Members of the General
Assembly
Steering At least once At any time upon written request of the Coordinator or any
Committee a month via 1/3 of the Members of the Steering Committee
tele or web-
conferencing
and at least
once a year
face to face.
10 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
6.2.2.2 Notice of a meeting
The chairperson of a Consortium Body shall give notice in writing of a meeting to each
Member of that Consortium Body as soon as possible and no later than the minimum number
of days preceding the meeting as indicated below.
Ordinary meeting Extraordinary meeting
General Assembly 45 calendar days 15 calendar days
Steering 14 calendar days 7 calendar days
Committee
6.2.2.3 Sending the agenda
The chairperson of a Consortium Body shall prepare and send each Member of that
Consortium Body a written (original) agenda no later than the minimum number of days
preceding the meeting as indicated below.
General Assembly 21 calendar days, 10 calendar days for an extraordinary meeting
Steering Committee 7 calendar days
6.2.2.4 Adding agenda items:
Any agenda item requiring a decision by the Members of a Consortium Body must be
identified as such on the agenda.
Any Member of a Consortium Body may add an item to the original agenda by written
notification to all of the other Members of that Consortium Body up to the minimum number
of days preceding the meeting as indicated below.
General Assembly 14 calendar days, 7 calendar days for an extraordinary meeting
Steering Committee 2 calendar days
6.2.2.5
During a meeting, the Members of a Consortium Body present or represented can
unanimously agree to add a new item to the original agenda.
6.2.2.6
Meetings of each Consortium Body may also be held by teleconference or other
telecommunication means.
6.2.2.7
Decisions will only be binding once the relevant part of the Minutes has been accepted
according to Section 6.2.5.
6.2.2.8
Any decision may also be taken without a meeting if the Coordinator circulates to all
Members of the Consortium Body a written document, which is then agreed by the defined
majority (see Section 6.2.3) of all Members of the Consortium Body. Such document shall
include the deadline for responses.
Decisions taken without a meeting shall be considered as accepted if, within the period set
out in article 6.2.4.4, no Member has sent an objection in writing to the chairperson. The
decisions will be binding after the chairperson sends to all Members of the Consortium Body
and to the Coordinator a written notification of this acceptance.
11 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
6.2.3 Voting rules and quorum
6.2.3.1
Each Consortium Body shall not deliberate and decide validly unless two-thirds (2/3) of its
Members are present or represented (quorum). If the quorum is not reached, the chairperson
of the Consortium Body shall convene another ordinary meeting within 15 calendar days. If in
this meeting the quorum is not reached once more, the chairperson shall convene an
extraordinary meeting, which shall be entitled to decide even if less than the quorum of
Members are present or represented.
6.2.3.2
Voting rules means one vote per Competent Authority (CA).
6.2.3.3
A Beneficiary which the General Assembly has declared according to Section 4.2 to be a
Defaulting Beneficiary may not vote.
6.2.3.4
Decisions shall be taken by a majority of two-thirds (2/3) of the votes cast.
6.2.4 Veto rights
6.2.4.1
A Member which can show that its own work, time for performance, costs, liabilities,
intellectual property rights or other legitimate interests would be severely affected by a
decision of a Consortium Body may exercise a veto with respect to the corresponding
decision or relevant part of the decision.
6.2.4.2
When the decision is foreseen on the original agenda, a Member may veto such a decision
during the meeting only.
6.2.4.3
When a decision has been taken on a new item added to the agenda before or during the
meeting, a Member may veto such decision during the meeting and within 15 calendar days
after the draft minutes of the meeting are sent.
6.2.4.4
When a decision has been taken without a meeting, a Member may veto such decision within
15 calendar days after written notification by the chairperson of the outcome of the vote.
6.2.4.5
In case of exercise of veto, the Members of the related Consortium Body shall make every
effort to resolve the matter, which occasioned the veto to the general satisfaction of all its
Members.
6.2.4.6
A Beneficiary may neither veto decisions relating to its identification to be in breach of its
obligations nor to its identification as a Defaulting Beneficiary. The Defaulting Beneficiary
may not veto decisions relating to its participation and termination in the consortium or the
consequences of them.
12 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
6.2.4.7
A Beneficiary requesting to leave the consortium may not veto decisions relating thereto.
6.2.5 Minutes of meetings
6.2.5.1
The chairperson of a Consortium Body shall produce written minutes of each meeting, which
shall be the formal record of all decisions taken. He/she shall send the draft minutes to all
Members within 10 calendar days of the meeting.
6.2.5.2
The minutes shall be considered as accepted if, within 15 calendar days from sending, no
Member has sent an objection in writing to the chairperson with respect to the accuracy of
the draft of the minutes.
6.2.5.3
The chairperson shall send the accepted minutes to all the Members of the Consortium Body
and to the Coordinator, who shall safeguard them. If requested the Coordinator shall provide
authenticated duplicates to Beneficiaries.
6.3 Specific operational procedures for the Consortium Bodies
6.3.1 General Assembly
In addition to the rules described in Section 6.2, the following rules apply:
6.3.1.1 Members
6.3.1.1.1
The General Assembly will be chaired by the Joint Action Coordinator and contain
representatives from each of the Competent Authorities and their Affiliated entities. This
plenary assembly will be the ultimate decision-making body in JADECARE.
A general assembly of all entities with decision-making responsibility in matters affecting the
overall project strategy, major work plan updates composition of the Consortium, effort and
budget re-assignment.
In the voting in the General Assembly, each Beneficiary/Competent Authority has one vote
(hereinafter General Assembly Member).
6.3.1.1.2
Each General Assembly Member shall be deemed to be duly authorised to deliberate,
negotiate and decide on all matters listed in Section 6.3.1.2. of this Consortium Agreement.
6.3.1.1.3
The Coordinator shall chair all meetings of the General Assembly, unless decided otherwise
in a meeting of the General Assembly.
6.3.1.1.4
The Beneficiaries agree to abide by all decisions of the General Assembly. This does not
prevent the Beneficiaries to submit a dispute to resolution in accordance with the provisions
of Settlement of disputes in Section 11.8.
13 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
6.3.1.2 Decisions
The General Assembly shall be free to act on its own initiative to formulate proposals and
take decisions in accordance with the procedures set out herein. In addition, all proposals
made by the Steering Committee shall also be considered and decided upon by the General
Assembly.
The following decisions shall be taken by the General Assembly:
As regards content, finances and intellectual property rights
Proposals for changes to Annexes 1 and 2 of the Grant Agreement to be agreed by the
Funding Authority
Changes to the Consortium Plan
Additions to Attachment 2 (Identified Affiliated Entities)
As regards evolution of the consortium
Entry of a new Beneficiary to the consortium and approval of the settlement on the
conditions of the accession of such a new Beneficiary
Withdrawal of a Beneficiary from the consortium and the approval of the settlement on
the conditions of the withdrawal
Identification of a breach by a Beneficiary of its obligations under this Consortium
Agreement or the Grant Agreement
Declaration of a Beneficiary to be a Defaulting Beneficiary
Remedies to be performed by a Defaulting Beneficiary
Termination of a Defaulting Beneficiary’s participation in the consortium and measures
relating thereto
Proposal to the Funding Authority for a change of the Coordinator
Proposal to the Funding Authority for suspension of all or part of the Joint Action
Proposal to the Funding Authority for termination of the Joint Action and the Consortium
Agreement
As regards appointments
On the basis of the Grant Agreement, the appointment if necessary of:
- Steering Committee Members
6.3.2 Steering Committee
In addition to the rules in Section 6.2, the following rules shall apply:
6.3.2.1 Members
The Steering Committee shall consist of an operational body comprising the Coordination
Team and the WP Leads (Lead Beneficiary, Leading and Co-Leading Executive
Organisations) as a decision making body on daily running of the project, with prerogatives
regarding minor updates, and effort/budget re-assignment as well as conflict resolution.
The Coordinator shall chair all meetings of the Steering Committee, unless decided
otherwise in a meeting of the Steering Committee.
14 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
6.3.2.2 Minutes of meetings
Minutes of Steering Committee meetings, once accepted, shall be sent by the Coordinator to
the General Assembly Members for information.
6.3.2.3 Tasks
6.3.2.3.1
The Steering Committee shall prepare the meetings, propose decisions and prepare the
agenda of the General Assembly according to Section 6.3.1.2.
6.3.2.3.2
The Steering Committee shall seek a consensus among the Beneficiaries.
6.3.2.3.3
The Steering Committee shall be responsible for the proper execution and implementation of
the decisions of the General Assembly.
6.3.2.3.4
The Steering Committee shall monitor the effective and efficient implementation of the Joint
Action.
6.3.2.3.5
In addition, the Steering Committee shall collect information at least every 6 months on the
progress of the Joint Action, examine that information to assess the compliance of the Joint
Action with the Consortium Plan and, if necessary, propose modifications of the Consortium
Plan to the General Assembly.
6.3.2.3.6
The Steering Committee shall be in charge of:
following up progress in each of the critical areas and the planning of tasks and activities;
monitoring the technical quality of the work and coordination between WP Leads;
conflict resolution;
establishment of mitigation plans to reduce the impact of potential risks;
effort/budget re-assignment;
constituting committees for matters that require specific attention (such as security, new
technological issues, gender equality, etc.) and establishing working procedures for such
committees;
supporting the Coordinator in preparing meetings with the Funding Authority and in
preparing related data and deliverables;
preparing the content and timing of press releases and joint publications by the
consortium or proposed by the Funding Authority in respect of the procedures of the
Grant Agreement Article 29.
6.3.2.3.7
In the case of abolished tasks as a result of a decision of the General Assembly, the Steering
Committee shall advise the General Assembly on ways to rearrange tasks and budgets of
the Beneficiaries concerned. Such rearrangement shall take into consideration the legitimate
commitments taken prior to the decisions, which cannot be cancelled.
15 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
6.4 Coordinator
6.4.1
The Coordinator shall be the intermediary between the Beneficiaries and the Funding
Authority and shall perform all tasks assigned to it as described in the Grant Agreement and
in this Consortium Agreement.
6.4.2
In particular, the Coordinator shall be responsible for:
monitoring compliance by the Beneficiaries with their obligations;
keeping the address list of Members and other contact persons updated and
available;
collecting, reviewing to verify consistency and submitting reports, other deliverables
(including financial statements and related certifications) and specific requested
documents to the Funding Authority;
transmitting documents and information connected with the Joint Action to any other
Beneficiaries concerned;
administering the financial contribution of the Funding Authority and fulfilling the
financial tasks described in Section 7.3;
providing, upon request, the Beneficiaries with official copies or originals of
documents that are in the sole possession of the Coordinator when such copies or
originals are necessary for the Beneficiaries to present claims.
Before sending any proposal for amendment to Grant Agreement to the EC on behalf of the
Beneficiaries, the Coordinator will inform all Beneficiaries in advance and present the
documents in question to those Beneficiaries that ask for it. The Coordinator will wait to
receive the explicit acceptance of the Beneficiaries which shall not be unreasonably withheld.
The terms and conditions of the signed documents are only binding for the Beneficiaries if
their explicit acceptance have been given prior to the time of the signature. If no answer is
received by the Coordinator from a Beneficiary before the deadline established in the
communication sent, it will be assumed that such silent Beneficiary accepts the content of
the amendment.
If one or more of the Beneficiaries is late in submission of any Joint Action deliverable, the
Coordinator may nevertheless submit the other ’Beneficiaries’ Joint Action deliverables and
all other documents required by the Grant Agreement to the Funding Authority in time.
6.4.3
If the Coordinator fails in its coordination tasks, the General Assembly may propose to the
Funding Authority to change the Coordinator.
6.4.4
The Coordinator shall not be entitled to act or to make legally binding declarations on behalf
of any other Beneficiary or of the consortium, unless explicitly stated otherwise in the Grant
Agreement or this Consortium Agreement.
6.4.5
The Coordinator shall not enlarge its role beyond the tasks specified in this Consortium
Agreement and in the Grant Agreement.
16 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
6.5 Coordination Team
KRONIKGUNE assumes the role of JA Coordinator, being the organization representing the
JADECARE Consortium. It is responsible for the achievement of the JA goals and the
contractual obligations towards the European Commission, and provides global scientific and
technical leadership, quality assurance policy and overall coordination of the joint action. The
Coordinator Team is formed by the JA Coordinator supported by the Scientific Coordinator,
the Project Manager and the Financial Manager.
6.6 Work Package Lead (WPL)
The WPL is performed by the Lead Beneficiary (LB), the Leading Executive Organization
(LEO) and the co-Leading Executive Organisation. LEO and co-Leading Executive
Organisation have the responsibility for day-to-day management and coordination of the
activities included in their respective work packages as defined in the work plan, implement
solutions for problems, supervise Task Leaders, produce the corresponding deliverables,
identify risks as early as possible and follow them up, and report to the PM about the
progress achieved against that planned. They are able to raise proposals to the SC
regarding effort and budget redistribution, and re-assignment of roles and responsibilities
within their respective WPs. WP participants meets at least once a month via tele- or web-
conferencing.
6.7 Next Adopters Working Groups (NAWG)
The NAWGs include local stakeholders in all the participating countries.
A Next Adopters Working Group (NAWG) is created in each of the next adopter sites for the
implementation of the Local Good Practices, led by the representative of the corresponding
Competent Authority or Affiliated Entity. NAWGs are supported by the responsible of the
original Good Practices as described in the transfer WPs (WP5-8). The NAWG includes a
representative of health systems, healthcare professionals, community members and third
sector. All members of each next adopter team shall meet regularly in order to share their
experiences and learn from them, suggest improvements, receive and provide support, plan
different measures, review objectives, and collect and deliver good practices. During these
meetings, the Competent Authority or affiliated Entity representative shall inform the
members of the team about the progress of the intervention in the other areas, highlighting
any problematic situation or any issues raised.
6.8 Policy Board (PB)
The PB is an external board composed by representatives of all Competent Authorities
involved in JADECARE that are MoHs, national focal points for Health Programme at the
European Commission (or other representatives of MSs identified by them) from other
Member States from EU and EEA, and all other policy-oriented stakeholders that
implementers will identify as important based on their sustainability-related analyses. The
role of the Policy Board shall be to give input to sustainability plans from the focus of policy,
and the definition of core messages to support evidence-based policy making with respect to
sustainability of JADECARE results. The PB has a key role in guaranteeing the sustainability
of the Joint Action and the impact after the end of the project. The Policy board shall be
established and coordinated by WP4 Lead with support of the Coordination Team.
17 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
7 Section: Financial provisions
7.1 General Principles
7.1.1 Distribution of Financial Contribution
The financial contribution of the Funding Authority to the Joint Action shall be distributed by
the Coordinator according to:
the Consortium Plan,
the approval of reports by the Funding Authority, and
the provisions of payment in Section 7.3.
A Beneficiary shall be funded only for its tasks carried out in accordance with the Consortium
Plan.
7.1.2 Justifying Costs
In accordance with its own usual accounting and management principles and practices, each
Beneficiary shall be solely responsible for justifying its costs with respect to the Joint Action
towards the Funding Authority. Neither the Coordinator nor any of the other Beneficiaries
shall be in any way liable or responsible for such justification of costs towards the Funding
Authority. Each Beneficiary will establish the necessary legal, administrative and/or
operational arrangements with their Affiliated Entities to ensure the correct justification of the
costs incurred.
7.1.3 Funding Principles
A Beneficiary that spends less than its allocated share of the budget as set out in the
Consortium Plan or implements less units than foreseen in the Consortium Plan will be
funded in accordance with its actual duly justified eligible costs only.
A Beneficiary that spends more than its allocated share of the budget as set out in the
Consortium Plan will be funded only in respect of duly justified eligible costs up to an amount
not exceeding that share.
7.1.4 Return of excess payments; receipts
In any case of a Beneficiary having received excess payments, the Beneficiary has to return
the relevant amount to the Coordinator without undue delay.
In case a Beneficiary earns any receipt that is deductible from the total funding as set out in
the Consortium Plan, the deduction is only directed toward the Beneficiary earning such
income. The other Beneficiaries’ financial share of the budget shall not be affected by one
Beneficiary’s receipt. In case the relevant receipt is more than the allocated share of the
Beneficiary as set out in the Consortium Plan, the Beneficiary shall reimburse the funding
reduction suffered by other Beneficiaries.
7.1.5 Financial Consequences of the termination of the participation of a Beneficiary
A Beneficiary leaving the consortium shall refund all payments it has received except the
amount of contribution accepted by the Funding Authority or another contributor.
Furthermore, a Defaulting Beneficiary shall, within the limits specified in Section 5.2 of this
Consortium Agreement, bear any reasonable and justifiable additional costs occurring to the
other Beneficiaries in order to perform its and their tasks.
18 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
7.2 Budgeting
The budget set out in the Consortium Plan shall be valued in accordance with the usual
accounting and management principles and practices of the respective Beneficiaries.
7.3 Payments
7.3.1 Payments to Beneficiaries are the exclusive tasks of the Coordinator.
In particular, the Coordinator shall:
Notify the Beneficiary concerned promptly of the date and composition of the amount
transferred to its bank account, giving the relevant references.
Perform diligently its tasks in the proper administration of any funds and in maintaining
financial accounts.
Undertake to keep the Funding Authority’s financial contribution to the Joint Action
separated from its normal business accounts, its own assets and property, except if the
Coordinator is a Public Body or is not entitled to do so due to statutory legislation.
With reference to Articles 16.2 and 16.3.2 of the Grant Agreement, no Beneficiary shall
before the end of the Joint Action receive more than its allocated share of the maximum
grant amount from which the amounts retained by the Funding Authority for the final
payment have been deducted.
7.3.2 Payment schedule
The payment schedule, which contains the transfer of pre-financing and interim payments to
Beneficiaries, will be handled after receipt from the Funding Authority according to the
following:
The Beneficiaries agree that the Funding Authority´s total pre-financing will be paid once the
Consortium Agreement has been signed by all beneficiaries.
Funding of costs included in the Consortium plan will be paid to Beneficiaries after receipt
from the Funding Authority without unjustified delay and in conformity with the provisions of
the Grant Agreement. Costs accepted by the Funding Authority will be paid to the Beneficiary
concerned.
The Coordinator is entitled to withhold any payments due to a Beneficiary identified by a
responsible Consortium Body to be in breach of its obligations under this Consortium
Agreement or the Grant Agreement or to a Beneficiary which has not yet signed this
Consortium Agreement.
The Coordinator is entitled to recover any payments already paid to a Defaulting Beneficiary.
The Coordinator is equally entitled to withhold payments to a Beneficiary when this is
suggested by or agreed with the Funding Authority.
8 Section: Results
8.1 Ownership of Results
Results are owned by the Beneficiary that generates them.
8.2 Joint ownership
Joint ownership is governed by Grant Agreement Article 19.2 with the following additions:
Unless otherwise agreed:
19 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
- each of the joint owners shall be entitled to use their jointly owned Results for non-
commercial research activities on a royalty-free basis, and without requiring the prior
consent of the other joint owner(s), and
- each of the joint owners shall be entitled to otherwise Exploit the jointly owned Results and
to grant non-exclusive licenses to third parties (without any right to sub-license), if the other
joint owners are given:
a) at least 45 calendar days advance notice with a right for the other joint owners to
object hereto at the latest 15 days after receipt of such notice, but only if the objecting
joint owner's legitimate academic or commercial interests are compromised; and
b) if no objection is made within the time limit stated above, the permission is given by
the other joint owners who each shall receive Fair and Reasonable compensation
taking into account each joint owner's relative contribution to the jointly owned
Results.
8.3 Transfer of Results
8.3.1
Each Beneficiary may transfer ownership of its own Results following the procedures of the
Grant Agreement Article n°19.
8.3.2
It may identify specific third Beneficiaries it intends to transfer the ownership of its Results to
in Attachment (2) to this Consortium Agreement. The other Beneficiaries hereby waive their
right to prior notice and their right to object to a transfer to listed third Beneficiaries according
to the Grant Agreement Article 19.
8.3.3
The transferring Beneficiary shall, however, at the time of the transfer, inform the other
Beneficiaries of such transfer and shall ensure that the rights of the other Beneficiaries will
not be affected by such transfer. Any addition to Attachment (2) after signature of this
Agreement requires a decision of the General Assembly.
8.3.4
The Beneficiaries recognize that in the framework of a merger or an acquisition of an
important part of its assets, it may be impossible under applicable EU and national laws on
mergers and acquisitions for a Beneficiary to give the full 45 calendar days prior notice for
the transfer as foreseen in the Grant Agreement.
8.3.5
The obligations above apply only for as long as other Beneficiaries still have - or still may
request - Access Rights to the Results.
8.4 Dissemination
8.4.1
For the avoidance of doubt, nothing in this Section 8.4 has impact on the confidentiality
obligations set out in Section 10.
20 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
8.4.2 Dissemination of own Results
8.4.2.1
During the Joint Action and for a period of 1 year after the end of the Joint Action, the
dissemination of own Results by one or several Beneficiaries including but not restricted to
publications and presentations, shall be governed by the procedure of Article 22 of the Grant
Agreement subject to the following provisions.
Prior notice of any planned publication shall be given to the other Beneficiaries at least 45
calendar days before the publication. Any objection to the planned publication shall be made
in accordance with the Grant Agreement in writing to the Coordinator and to the Beneficiary
or Beneficiaries proposing the dissemination within 30 calendar days after receipt of the
notice. If no objection is made within the time limit stated above, the publication is permitted.
8.4.2.2
An objection is justified if
(a) the protection of the objecting Beneficiary's Results would be adversely affected
(b) the objecting Beneficiary's legitimate interests in relation to the Results would be
significantly harmed.
The objection has to include a precise request for necessary modifications.
8.4.2.3
If an objection has been raised the involved Beneficiaries shall discuss how to overcome the
justified grounds for the objection on a timely basis (for example by amendment to the
planned publication and/or by protecting information before publication) and the objecting
Beneficiary shall not unreasonably continue the opposition if appropriate measures are taken
following the discussion.
8.5
The objecting Beneficiary can request a publication delay of not more than 90 calendar days
from the time it raises such an objection. After 90 calendar days, the publication is permitted,
provided that reasonable modifications of the objecting Party have been implemented in the
Publication as indicated by the objecting Party.
8.5.1 Dissemination of another Beneficiary’s unpublished Results
A Beneficiary shall not include in any dissemination activity another Beneficiary's Results
without obtaining the owning Beneficiary's prior written approval, unless they are already
published, in which case, in addition, the owning Beneficiary has to be informed. The mere
absence of an objection is not considered as an approval.
8.5.2 Cooperation obligations
The Beneficiaries undertake to cooperate to allow the timely submission, examination,
publication and defense of any dissertation or thesis for a degree that includes their Results
subject to the confidentiality and publication provisions agreed in this Consortium Agreement.
8.5.3 Use of names, logos or trademarks
Nothing in this Consortium Agreement shall be construed as conferring rights to use in
advertising, publicity or otherwise the name of the Beneficiaries or any of their logos or
trademarks without their prior written approval.
21 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
9 Section: Access Rights
9.1 General Principles
9.1.1
Each Beneficiary shall implement its tasks in accordance with the Consortium Plan and shall
bear sole responsibility for ensuring that its acts within the Joint Action do not knowingly
infringe Affiliated Entity property rights.
9.1.2
Any Access Rights granted expressly exclude any rights to sublicense unless expressly
stated otherwise.
9.1.3
Access Rights shall be free of any administrative transfer costs.
9.1.4
Access Rights are granted on a non-exclusive basis.
9.1.5
Results and Background shall be used only for the purposes for which Access Rights to it
have been granted.
9.1.6
All requests for Access Rights shall be made in writing. The granting of Access Rights may
be made conditional on the acceptance of specific conditions aimed at ensuring that these
rights will be used only for the intended purpose and that appropriate confidentiality
obligations are in place. For the avoidance of doubt, this means that the owning Beneficiary
may impose to the Beneficiary requesting an Access Right the execution of a separate
license agreement, this separate license agreement should be in line with the Consortium
Agreement.
9.1.7
The requesting Beneficiary must show that the Access Rights are needed.
9.2 Access Rights for implementation
Access Rights to Results needed for the performance of the own work of a Beneficiary under
the Joint Action shall be granted on a royalty-free basis.
9.3 Access Rights for Exploitation
9.3.1 Access Rights to Results
Access Rights to Results if Needed for Exploitation of a Beneficiary's own Results shall be
granted on a royalty-free basis.
9.3.2
Access Rights to Background if Needed for Exploitation of a Beneficiary’s own Results,
including for research on behalf of an Affiliated Entity, shall be granted on Fair and
Reasonable conditions.
22 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
9.3.3
A request for Access Rights may be made up to twelve months after the end of the Joint
Action or, in the case of Section 9.6.2.1.2, after the termination of the requesting
Beneficiary’s participation in the Joint Action.
9.4 Access Rights for Affiliated Entities
Affiliated Entities have Access Rights under the conditions of the Grant Agreement Article 19
if they are identified in [Attachment 2 (Identified Affiliated Entities) to this Consortium
Agreement].
Such Access Rights must be requested by the Affiliated Entity from the Beneficiary that holds
the Results. Alternatively, the Beneficiary granting the Access Rights may individually agree
with the Beneficiary requesting the Access Rights to have the Access Rights include the right
to sublicense to the latter's Affiliated Entities [listed in Attachment 2]. Access Rights to
Affiliated Entities shall be granted on Fair and Reasonable conditions and upon written
bilateral agreement.
Affiliated Entities which obtain Access Rights in return fulfil all confidentiality and other
obligations accepted by the Beneficiaries under the Grant Agreement or this Consortium
Agreement as if such Affiliated Entities were Beneficiaries.
Access Rights may be refused to Affiliated Entities if such granting is contrary to the
legitimate interests of the Beneficiary which owns the Results.
Access Rights granted to any Affiliated Entity are subject to the continuation of the Access
Rights of the Beneficiary to which it is affiliated, and shall automatically terminate upon
termination of the Access Rights granted to such Beneficiary.
Upon cessation of the status as an Affiliated Entity, any Access Rights granted to such
former Affiliated Entity shall lapse.
Further arrangements with Affiliated Entities may be negotiated in separate agreements.
9.5 Additional Access Rights
The Beneficiaries agree to negotiate in good faith any additional Access Rights to Results as
might be asked for by any Beneficiary, upon adequate financial conditions to be agreed.
9.6 Access Rights for Beneficiaries entering or leaving the consortium
9.6.1 New Beneficiaries entering the consortium
As regards Results developed before the accession of the new Beneficiary, the new
Beneficiary will be granted Access Rights on the conditions applying for Access Rights to
Background.
23 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
9.6.2 Beneficiaries leaving the consortium
9.6.2.1 Access Rights granted to a leaving Beneficiary
9.6.2.1.1 Defaulting Beneficiary
Access Rights granted to a Defaulting Beneficiary and such Beneficiary's right to request
Access Rights shall cease immediately upon receipt by the Defaulting Beneficiary of the
formal notice of the decision of the General Assembly to terminate its participation in the
consortium.
9.6.2.1.2 Non-defaulting Beneficiary
A non-defaulting Beneficiary leaving voluntarily and with the other Beneficiaries' consent
shall have Access Rights to the Results developed until the date of the termination of its
participation.
It may request Access Rights within the period specified in Section 9.3.3.
9.6.2.2 Access Rights to be granted by any leaving Beneficiary
Any Beneficiary leaving the Joint Action shall continue to grant Access Rights pursuant to the
Grant Agreement and this Consortium Agreement as if it had remained a Beneficiary for the
whole duration of the Joint Action.
9.7 Specific Provisions for Access Rights to Software
For the avoidance of doubt, the general provisions for Access Rights provided for in this
Section 9 are applicable also to Software.
Beneficiaries’ Access Rights to Software do not include any right to receive source code or
object code ported to a certain hardware platform or any right to receive respective Software
documentation in any particular form or detail, but only as available from the Beneficiary
granting the Access Rights.
10 Section: Non-disclosure of information
10.1
All information in whatever form or mode of communication, which is disclosed by a
Beneficiary (the “Disclosing Beneficiary”) to any other Beneficiary (the “Recipient”) in
connection with the Joint Action during its implementation and which has been explicitly
marked as “confidential” at the time of disclosure, or when disclosed orally has been
identified as confidential at the time of disclosure and has been confirmed and designated in
writing within 15 calendar days from oral disclosure at the latest as confidential information
by the Disclosing Beneficiary, is “Confidential Information”.
10.2
The Recipients hereby undertake in addition and without prejudice to any commitment on
non-disclosure under the Grand Agreement, for a period of 4 years after the end of the Joint
Action:
Not to use Confidential Information otherwise than for the purpose for which it was
disclosed;
not to disclose Confidential Information without the prior written consent by the Disclosing
Beneficiary;
24 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
to ensure that internal distribution of Confidential Information by a Recipient shall take
place on a strict need-to-know basis; and
to return to the Disclosing Beneficiary, or destroy, on request all Confidential Information
that has been disclosed to the Recipients including all copies thereof and to delete all
information stored in a machine-readable form to the extent practically possible. The
Recipients may keep a copy to the extent it is required to keep, archive or store such
Confidential Information because of compliance with applicable laws and regulations or
for the proof of on-going obligations provided that the Recipient comply with the
confidentiality obligations herein contained with respect to such copy for as long as the
copy is retained.
10.3
The recipients shall be responsible for the fulfilment of the above obligations on the part of
their employees or Affiliated Entities involved in the Joint Action and shall ensure that they
remain so obliged, as far as legally possible, during and after the end of the Joint Action
and/or after the termination of the contractual relationship with the employee or Affiliated
Entity.
10.4
The above shall not apply for disclosure or use of Confidential Information, if and in so far as
the Recipient can show that:
the Confidential Information has become or becomes publicly available by means other
than a breach of the Recipient’s confidentiality obligations;
the Disclosing Beneficiary subsequently informs the Recipient that the Confidential
Information is no longer confidential;
the Confidential Information is communicated to the Recipient without any obligation of
confidentiality by an Affiliated Entity who is to the best knowledge of the Recipient in
lawful possession thereof and under no obligation of confidentiality to the Disclosing
Beneficiary;
the disclosure or communication of the Confidential Information is foreseen by provisions
of the Grant Agreement;
the Confidential Information, at any time, was developed by the Recipient completely
independently of any such disclosure by the Disclosing Beneficiary;
the Confidential Information was already known to the Recipient prior to disclosure, or
the Recipient is required to disclose the Confidential Information in order to comply with
applicable laws or regulations or with a court or administrative order, subject to the
provision Section 10.7 hereunder.
10.5
The Recipient shall apply the same degree of care with regard to the Confidential Information
disclosed within the scope of the Joint Action as with its own confidential and/or proprietary
information, but in no case less than reasonable care.
10.6
Each Beneficiary shall promptly advise the other Beneficiary in writing of any unauthorised
disclosure, misappropriation or misuse of Confidential Information after it becomes aware of
such unauthorised disclosure, misappropriation or misuse.
25 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
10.7
If any Beneficiary becomes aware that it will be required, or is likely to be required, to
disclose Confidential Information in order to comply with applicable laws or regulations or
with a court or administrative order, it shall, to the extent it is lawfully able to do so, prior to
any such disclosure
notify the Disclosing Beneficiary, and
comply with the Disclosing Beneficiary’s reasonable instructions to protect the
confidentiality of the information.
11 Section: Miscellaneous
11.1 Attachments, inconsistencies and severability
This Consortium Agreement consists of this core text and
- Attachment 1 (Accession document).
- Attachment 2 (Identified Affiliated Entities).
In case the terms of this Consortium Agreement are in conflict with the terms of the Grant
Agreement, the terms of the latter shall prevail. In case of conflicts between the attachments
and the core text of this Consortium Agreement, the latter shall prevail.
Should any provision of this Consortium Agreement become invalid, illegal or unenforceable,
it shall not affect the validity of the remaining provisions of this Consortium Agreement. In
such a case, the Beneficiaries concerned shall be entitled to request that a valid and
practicable provision be negotiated that fulfils the purpose of the original provision.
11.2 No representation, partnership or agency
Except as otherwise provided in Section 6.4.4, no Beneficiary shall be entitled to act or to
make legally binding declarations on behalf of any other Beneficiary or of the consortium.
Nothing in this Consortium Agreement shall be deemed to constitute a joint venture, agency,
partnership, interest grouping or any other kind of formal business grouping or entity between
the Beneficiaries.
11.3 Notices and other communication
Any notice to be given under this Consortium Agreement shall be in writing to the addresses
and recipients as listed in the most current address list kept by the Coordinator.
Formal notices:
If it is required in this Consortium Agreement (Sections 4.2, 9.6, 9.7 and 11.4) that a formal
notice, consent or approval shall be given, such notice shall be signed by an authorised
representative of a Beneficiary and shall either be served personally or sent by mail with
recorded delivery.
Other communication:
Other communication between the Beneficiaries may also be affected by other means such
as e-mail with acknowledgement of receipt, which fulfils the conditions of written form.
26 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
Any change of persons or contact details shall be notified immediately by the respective
Beneficiary to the Coordinator. The address list shall be accessible to all Beneficiaries.
11.4 Assignment and amendments
Except as set out in Section 8.3, no rights or obligations of the Beneficiaries arising from this
Consortium Agreement may be assigned or transferred, in whole or in part, to any Affiliated
Entity without the other Beneficiaries’ prior formal approval. Amendments and modifications
to the text of this Consortium Agreement not explicitly listed in Section 6.3 require a separate
written agreement to be signed among all Beneficiaries.
11.5 Mandatory national law
Nothing in this Consortium Agreement shall be deemed to require a Beneficiary to breach
any mandatory statutory law under which the Beneficiary is operating.
11.6 Language
This Consortium Agreement is drawn up in English, which language shall govern all
documents, notices, meetings, arbitral proceedings and processes relative thereto.
11.7 Applicable law
This Consortium Agreement shall be construed in accordance with and governed by the laws
of Belgium excluding its conflict of law provisions.
11.8 Settlement of disputes
The Beneficiaries shall endeavor to settle their disputes amicably.
The Beneficiaries agree that any dispute, controversy or claim arising under, out of or
relating to this Consortium Agreement and any subsequent amendments of this Consortium
Agreement, including, without limitation, its formation, validity, binding effect, interpretation,
performance, breach or termination (a "Dispute") which cannot be solved amicably, shall first
be submitted by the Beneficiaries to the Work Package Leader concerned. The Coordination
Team may be involved in the conflict resolution if requested by the Work Package Leader. In
case the Work Package Leader fails to reach an amicable agreement within 15 days from the
date on which the Dispute was referred to it, the Dispute shall be submitted to the Steering
Committee that will try to reach a solution by consensus within (15 days) from the date on
which the Dispute was referred to it. Disputes which cannot be settled amicably shall be
subject to the jurisdiction of the competent court in Brussels.
27 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (LR SAM),
Signature
Name: Gitana Ratkiene
Title: Ministry of Health of the Republic of Lithuania, Personal Health care Department,
Primary health care and nursing Division. Adviser
Date
40 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
Attachment 1: Accession document
ACCESSION
of a new Beneficiary to
[Acronym of the Joint Action] Consortium Agreement, version […, YYYY-MM-DD]
[OFFICIAL NAME OF THE NEW BENEFICIARY AS IDENTIFIED IN THE Grant Agreement]
hereby consents to become a Beneficiary to the Consortium Agreement identified above and
accepts all the rights and obligations of a Beneficiary starting [date].
[OFFICIAL NAME OF THE COORDINATOR AS IDENTIFIED IN THE Grant Agreement]
hereby certifies that the consortium has accepted in the meeting held on [date] the accession
of [the name of the new Beneficiary] to the consortium starting [date].
This Accession document has been done in 2 originals to be duly signed by the undersigned
authorised representatives.
[Date and Place]
[INSERT NAME OF THE NEW BENEFICIARY]
Signature(s)
Name(s)
Title(s)
[Date and Place]
[INSERT NAME OF THE COORDINATOR]
Signature(s)
Name(s)
Title(s)
45 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
Attachment 2: List of Affiliated Entities
FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA
REGION DE MURCIA (FFIS), affiliated or linked to KG
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD (FPS), affiliated or linked
to KG
Servicio Cántabro de Salud (SCS), affiliated or linked to KG
GERENCIA REGIONAL DE SALUD DE CASTILLA Y LEON (SACYL), affiliated or
linked to KG
CONSEJERIA DE SALUD y FAMILIAS DE LA JUNTA DE ANDALUCIA (CSFJA),
affiliated or linked to KG
FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA
(IDIVAL), affiliated or linked to KG
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
(IDIBAPS), affiliated or linked to KG
AGENCIA DE QUALITAT I AVALUACIO SANITARIES DE CATALUNYA (AQUAS),
affiliated or linked to KG
SERVICIO MURCIANO DE SALUD (SMS), affiliated or linked to KG
ZAVOD ZA JAVNO ZDRAVSTVO FEDERACIJEBOSNE I HERCEGOVINE
(ZZJZFBIH), affiliated or linked to MCA
MINISTARSTVO ZDRAVLJA I SOCIJALNE ZASTITE REPUBLIKE SRPSKE (MHSw-
RS), affiliated or linked to MCA
HRVATSKI ZAVOD ZA ZDRAVSTVENO OSIGURANJE (CHIF), affiliated or linked to
CIPH
FAKULTNI NEMOCNICE OLOMOUC (UHO), affiliated or linked to MZCR
REGION SYDDANMARK (RSD), affiliated or linked to RND
SIHTASUTUS VILJANDI HAIGLA (VH), affiliated or linked to MSAE
BAYERISCHES LANDESAMT FUR GESUNDHEIT UND
LEBENSMITTELSICHERHEIT (LGL), affiliated or linked to BAGSFI
ZTG ZENTRUM FUR TELEMATIK IM GESUNDHEITSWESEN GMBH (ZTG-GmBH),
affiliated or linked to BAGSFI
ARISTOTELIO PANEPISTIMIO THESSALONIKIS (AUTH), affiliated or linked to
4THYPE
SEMMELWEIS EGYETEM (SU-HSMTC), affiliated or linked to AEEK
JAHN FERENC DEL-PESTI KORHAZ ES RENDELOINTEZET (JFDPK), affiliated or
linked to AEEK
46 / 47
JADECARE Consortium Agreement - Final version , 2020-10-26
AZIENDA ULSS 4 VENETO ORIENTALE (PROMIS), affiliated or linked to AGENAS
REGIONE LOMBARDIA (LOMBARDIA), affiliated or linked to AGENAS
AZIENDA UNITA SANITARIA LOCALE UMBRIA 1 (UMBRIA), affiliated or linked to
AGENAS
MINISTERO DELLA SALUTE (MhH), affiliated or linked to AGENAS
REGIONE MARCHE (MARCHE), affiliated or linked to AGENAS
AGENZIA REGIONALE DI SANITA (TOSCANA), affiliated or linked to AGENAS
AZIENDA SANITARIA LOCALE NA 2 NORD (ASL NA2), affiliated or linked to
AGENAS
BERNU KLINISKA UNIVERSITATES SLIMNICA VALSTS SIA (CCUH), affiliated or
linked to NVD
SPMS - SERVICOS PARTILHADOS DO MINISTERIO DA SAUDE EPE (SPMS),
affiliated or linked to ACSS
UNIVERSIDADE NOVA DE LISBOA (ENSP/NOVA), affiliated or linked to ACSS
ZAVOD ZA ZDRAVSTVENO ZAVAROVANJE SLOVENIJE THE HEALTH
INSURANCE INSTITUTE OF SLOVENIA (ZZZS), affiliated or linked to NIJZ
47 / 47